专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130017265A1 PARTICLES FOR MULTIPLE AGENT DELIVERY 审中-公开
标题翻译：多种代理商交付的颗粒
公开(公告)号：US20130017265A1
公开(公告)日：2013-01-17
申请号：US13515668
申请日：2010-12-16
申请人： Omid C. Farokhzad , Nagesh Kolishetti , Shanta Dhar , Stephen J. Lippard , Robert S. Langer , Pedro M. Valencia
发明人： Omid C. Farokhzad , Nagesh Kolishetti , Shanta Dhar , Stephen J. Lippard , Robert S. Langer , Pedro M. Valencia
IPC分类号： A61K31/80 , A61K31/787 , C08G63/91 , A61P37/04 , A61P35/00 , A61K9/14 , A61K31/785
CPC分类号： A61K45/06 , A61K47/593 , A61K47/60 , A61K47/6937
摘要： Delivery compositions are provided that include two or more active agents, wherein at least one active agent is conjugated to a polymer. The delivery compositions allow for controlled release of multiple active agents, including active agents with varying solubility, charge, and/or molecular weight.
摘要翻译：提供包含两种或更多种活性剂的递送组合物，其中至少一种活性剂与聚合物缀合。递送组合物允许控制释放多种活性剂，包括具有不同溶解度，电荷和/或分子量的活性剂。

2. 发明授权

US08603532B2 Nanostructures for drug delivery 有权
标题翻译：用于药物输送的纳米结构
公开(公告)号：US08603532B2
公开(公告)日：2013-12-10
申请号：US13122615
申请日：2009-10-20
申请人： Stephen J. Lippard , Shanta Dhar , Omid C. Farokhzad , Frank X. Gu , Nagesh Kolishetti
发明人： Stephen J. Lippard , Shanta Dhar , Omid C. Farokhzad , Frank X. Gu , Nagesh Kolishetti
IPC分类号： A61K9/14 , A61K9/51
CPC分类号： A61K9/48 , A61K9/143 , A61K31/555 , A61K33/24 , A61K47/48092 , A61K47/48869 , A61K47/48915 , A61K47/549 , A61K47/6925 , A61K47/6937 , B82Y5/00
摘要： The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a plurality of particles comprising a platinum(IV) therapeutically active precursor.
摘要翻译：本发明提供了可用于治疗患有癌症或有癌症发生危险的受试者的组合物，制剂，制剂，试剂盒和方法。本发明的一些实施方案可以包含包含多个包含铂（IV）治疗活性前体的颗粒的组合物。

3. 发明申请

US20110300219A1 NANOSTRUCTURES FOR DRUG DELIVERY 有权
标题翻译：用于药物递送的纳米结构
公开(公告)号：US20110300219A1
公开(公告)日：2011-12-08
申请号：US13122615
申请日：2009-10-20
申请人： Stephen J. Lippard , Shanta Dhar , Omid C. Farokhzad , Frank X. Gu , Nagesh Kolishetti
发明人： Stephen J. Lippard , Shanta Dhar , Omid C. Farokhzad , Frank X. Gu , Nagesh Kolishetti
IPC分类号： A61K9/14 , A61P35/00 , A61K39/00 , A61K33/00 , A61K31/282
CPC分类号： A61K9/48 , A61K9/143 , A61K31/555 , A61K33/24 , A61K47/48092 , A61K47/48869 , A61K47/48915 , A61K47/549 , A61K47/6925 , A61K47/6937 , B82Y5/00
摘要： The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a plurality of particles comprising a platinum(IV) therapeutically active precursor.
摘要翻译：本发明提供了可用于治疗患有癌症或有癌症发生危险的受试者的组合物，制剂，制剂，试剂盒和方法。本发明的一些实施方案可以包含包含多个包含铂（IV）治疗活性前体的颗粒的组合物。

4. 发明授权

US09265747B2 Platinum (IV) complexes for use in dual mode pharmaceutical therapy 有权
标题翻译：用于双重模式药物治疗的铂（IV）复合物
公开(公告)号：US09265747B2
公开(公告)日：2016-02-23
申请号：US13060354
申请日：2009-08-26
申请人： Stephen J. Lippard , Shanta Dhar
发明人： Stephen J. Lippard , Shanta Dhar
IPC分类号： A61K31/282 , A61K31/19 , A61K33/24 , A61K45/06
CPC分类号： A61K31/282 , A61K31/19 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects in need of therapeutic protocol, including subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a first component comprising a precursor to a therapeutically active platinum agent and a precursor to a second therapeutically active agent. The therapeutically active platinum agent and the second therapeutically active agent may dissociate from each other, thereby forming a first therapeutically active platinum agent and a second therapeutically active agent. The second therapeutically active gent may affect a cellular pathway of a cancer cell and may be substantially inactive towards non-cancerous cells.
摘要翻译：本发明提供了可用于治疗需要治疗方案的受治疗者的组合物，制剂，制剂，试剂盒和方法，包括具有癌症或有发展癌症风险的受试者。本发明的一些实施方案可以包含包含第一组分的组合物，所述第一组分包含治疗活性铂剂的前体和第二治疗活性剂的前体。治疗活性的铂剂和第二治疗活性剂可以彼此解离，从而形成第一治疗活性的铂剂和第二治疗活性剂。第二治疗活性配偶可能影响癌细胞的细胞途径，并且可能对非癌细胞基本上无活性。

5. 发明申请

US20120244230A1 POLYVALENT POLYNUCLEOTIDE NANOPARTICLE CONJUGATES AS DELIVERY VEHICLES FOR A CHEMOTHERAPEUTIC AGENT 审中-公开
标题翻译：多价多核苷酸纳米粒子作为化学药剂的交付车辆
公开(公告)号：US20120244230A1
公开(公告)日：2012-09-27
申请号：US13393454
申请日：2010-09-01
申请人： Chad A. Mirkin , David A. Giljohann , Weston L. Daniel , Stephen J. Lippard , Shanta Dhar
发明人： Chad A. Mirkin , David A. Giljohann , Weston L. Daniel , Stephen J. Lippard , Shanta Dhar
IPC分类号： C07H21/00 , C12N5/02 , A61P35/00 , C07H21/04 , C07H21/02 , A61K33/24 , C07K2/00 , B82Y5/00
CPC分类号： B82Y5/00 , A61K47/6923
摘要： The present invention is directed to compositions and methods of delivering a chemotherapeutic agent via a polynueleotide-functionalized nanoparticle (PN-NP).
摘要翻译：本发明涉及通过多核苷酸官能化的纳米颗粒（PN-NP）递送化学治疗剂的组合物和方法。

6. 发明申请

US20110257261A1 PLATINUM (IV) COMPLEXES FOR USE IN DUAL MODE PHARMACEUTICAL THERAPY 有权
标题翻译：用于双模式药物治疗的白蛋白（IV）复合物
公开(公告)号：US20110257261A1
公开(公告)日：2011-10-20
申请号：US13060354
申请日：2009-08-26
申请人： Stephen J. Lippard , Shanta Dhar
发明人： Stephen J. Lippard , Shanta Dhar
IPC分类号： A61K31/282 , A61P35/00 , C07F15/00
CPC分类号： A61K31/282 , A61K31/19 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects in need of therapeutic protocol, including subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a first component comprising a precursor to a therapeutically active platinum agent and a precursor to a second therapeutically active agent. The therapeutically active platinum agent and the second therapeutically active agent may dissociate from each other, thereby forming a first therapeutically active platinum agent and a second therapeutically active agent. The second therapeutically active gent may affect a cellular pathway of a cancer cell and may be substantially inactive towards non-cancerous cells.
摘要翻译：本发明提供了可用于治疗需要治疗方案的受治疗者的组合物，制剂，制剂，试剂盒和方法，包括具有癌症或有发展癌症风险的受试者。本发明的一些实施方案可以包含包含第一组分的组合物，所述第一组分包含治疗活性铂剂的前体和第二治疗活性剂的前体。治疗活性的铂剂和第二治疗活性剂可以彼此解离，从而形成第一治疗活性的铂剂和第二治疗活性剂。第二治疗活性配偶可能影响癌细胞的细胞途径，并且可能对非癌细胞基本上无活性。

7. 发明申请

US20140303081A1 APOPTOSIS-TARGETING NANOPARTICLES 有权
公开(公告)号：US20140303081A1
公开(公告)日：2014-10-09
申请号：US14240081
申请日：2012-08-31
申请人： Shanta Dhar , Sean Marrache
发明人： Shanta Dhar , Sean Marrache
IPC分类号： A61K38/17 , A61K45/06 , A61K47/48 , A61K31/315 , A61K38/08
CPC分类号： A61K38/1709 , A61K31/315 , A61K38/08 , A61K45/06 , A61K47/54 , A61K47/549 , A61K47/6921 , A61K47/6935 , A61K47/6937 , A61K49/0067 , A61K49/0093 , A61K49/1881
摘要： Nanoparticles include a core and one or more targeting moieties, as well as one or more contrast agents or one or more therapeutic agents. The contrast agents or therapeutic agents may be contained or embedded within the core. If the nanoparticle includes therapeutic agents, the agents are preferably released from the core at a desired rate. The core may be biodegradable and may release the agents as the core is degraded or eroded. The targeting moieties preferably extend outwardly from the core so that they are available for interaction with cellular components, which interactions will target the nanoparticles to the appropriate cells, such as apoptotic cells; organelles, such as mitochondria; or the like. The targeting moieties may be tethered to the core or components that interact with the core.
摘要翻译：纳米颗粒包括核心和一个或多个靶向部分，以及一种或多种造影剂或一种或多种治疗剂。造影剂或治疗剂可以包含或嵌入核心内。如果纳米颗粒包括治疗剂，则试剂优选以所需的速率从芯中释放。核心可以是可生物降解的，并且当核心被降解或侵蚀时可释放药剂。靶向部分优选从核心向外延伸，使得它们可用于与细胞组分相互作用，所述相互作用将靶向纳米颗粒到合适的细胞，例如凋亡细胞; 细胞器，如线粒体; 或类似物。靶向部分可以连接到与核相互作用的核心或组分。

8. 发明授权

US09517277B2 Immune-stimulating photoactive hybrid nanoparticles 有权
标题翻译：免疫刺激光敏杂交纳米颗粒
公开(公告)号：US09517277B2
公开(公告)日：2016-12-13
申请号：US14128238
申请日：2012-07-11
申请人： Shanta Dhar , Joshua Choi , Sean Marrache
发明人： Shanta Dhar , Joshua Choi , Sean Marrache
IPC分类号： A61K51/00 , A61M36/14 , A61K47/48 , A61K41/00
CPC分类号： A61K47/48915 , A61K41/0071
摘要： Provides is a therapeutic technology that combines the phototoxic and immune-stimulating ability of photodynamic therapy with the widespread effectiveness of the immune system to reduce the viability of such as cancer cells and tumors. The nanoparticle compositions of the disclosure combine an immunostimulant with a photosensitizer using a nanoparticle delivery platform. For example, zinc pthalocyanine, which is a long-wavelength absorbing photosensitizer, integrated into a polymeric nanoparticle core made up of poly(D,L-lactic-co-glycolic acid)-b-poly(ethylene glycol) (PLGA-b-PEG). The outside surface of the core can be coated with metallic nanoparticles, which are then modified with CpG-ODN. Metastatic mouse breast carcinoma cells showed significant photocytotoxicity of the hybrid after irradiation with a 660 nm LASER light and this activity was remarkably better than either treatment alone. Treatment of mouse bone marrow derived dendritic cells with the photodynamic therapy-killed 4T1 cell lysate showed that the combination of photodynamic therapy with a synergistic immunostimulant in a single nanoparticle system resulted in an immune response suitable for the treatment of such as a metastatic cancer.
摘要翻译：提供一种治疗技术，将光动力疗法的光毒性和免疫刺激能力与免疫系统的广泛功效结合起来，以降低癌细胞和肿瘤的生存能力。本公开的纳米颗粒组合物使用纳米颗粒递送平台将免疫刺激剂与光敏剂组合。例如，作为长波长吸收光敏剂的锌酞菁聚合在由聚（D，L-乳酸 - 共 - 乙醇酸）-b-聚（乙二醇）（PLGA-b- PEG）。芯的外表面可以涂覆金属纳米粒子，然后用CpG-ODN进行修饰。转移性小鼠乳腺癌细胞在用660nm激光照射后显示杂合物的显着的光细胞毒性，并且该活性明显优于单独的任一种治疗。用光动力治疗杀死的4T1细胞裂解物处理小鼠骨髓来源的树突状细胞显示，在单个纳米颗粒系统中光动力学治疗与协同免疫刺激剂的组合导致适合于治疗诸如转移性癌症的免疫应答。

9. 发明授权

US09901616B2 Apoptosis-targeting nanoparticles 有权
公开(公告)号：US09901616B2
公开(公告)日：2018-02-27
申请号：US14240081
申请日：2012-08-31
申请人： Shanta Dhar , Sean Marrache
发明人： Shanta Dhar , Sean Marrache
IPC分类号： A61K38/17 , A61K49/00 , A61K49/18 , A61K31/315 , A61K38/08 , A61K45/06 , A61K47/54 , A61K47/69
CPC分类号： A61K38/1709 , A61K31/315 , A61K38/08 , A61K45/06 , A61K47/54 , A61K47/549 , A61K47/6921 , A61K47/6935 , A61K47/6937 , A61K49/0067 , A61K49/0093 , A61K49/1881
摘要： Nanoparticles include a core and one or more targeting moieties, as well as one or more contrast agents or one or more therapeutic agents. The contrast agents or therapeutic agents may be contained or embedded within the core. If the nanoparticle includes therapeutic agents, the agents are preferably released from the core at a desired rate. The core may be biodegradable and may release the agents as the core is degraded or eroded. The targeting moieties preferably extend outwardly from the core so that they are available for interaction with cellular components, which interactions will target the nanoparticles to the appropriate cells, such as apoptotic cells; organelles, such as mitochondria; or the like. The targeting moieties may be tethered to the core or components that interact with the core.

10. 发明申请

US20170367989A1 NANOPARTICLES FOR LIPID HOMEOSTASIS 审中-公开
公开(公告)号：US20170367989A1
公开(公告)日：2017-12-28
申请号：US15536832
申请日：2015-12-22
申请人： Shanta DHAR , Sean MARRACHE , Ru WEN , Bhabatosh BANIK , UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
发明人： Shanta Dhar , Sean Marrrache , Ru Wen , Bhabatosh Banik
IPC分类号： A61K9/51 , A61K49/18 , A61K9/28 , A61K47/69 , A61K9/127 , A61K47/54 , B82Y5/00 , A61K45/06
CPC分类号： A61K9/5153 , A61K9/1275 , A61K9/282 , A61K38/10 , A61K45/06 , A61K47/54 , A61K47/549 , A61K47/6927 , A61K47/6937 , A61K49/1824 , B82Y5/00
摘要： Nanoparticles include a polymeric core and a high density lipoprotein (HDL) component where the ratio by weight of the HDL component to the polymeric core is in a range from about 1:9 to about 9:1, such as about 75:25 or less or about 7:3 or less. The nanoparticles may also include a mitochondria targeting moiety. The nanoparticles may be used to treat or prevent atherosclerosis or to maintain lipid homeostasis.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式